Prospective Grant of Exclusive License: Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) as a Novel Treatment for Multiple Sclerosis

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. provisional patent application 60/393,021 (DHHS ref. no. E-143-2002/0- US-01) filed June 28, 2002, international PCT application PCT/US02/ 38290 (DHHS ref. no. E-143-2002/0-PCT-02), international PCT application PCT/US03/20428 (DHHS ref. no. E-143-2002/0-PCT-04), and United States Patent Application Serial No. 10/607,598 (DHHS ref. no. E-143-2002/0-US-03), all entitled, "Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) As A Novel Treatment for Multiple Sclerosis," and all corresponding foreign patent applications to Protein Design Laboratories, of Fremont, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide. The field of use may be limited to the treatment of multiple sclerosis using monoclonal antibodies against the interleukin-2 receptor.